Clinical Trial Update: Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating brigatinib after definitive chemoradiotherapy in ALK-rearranged stage III non-small cell lung cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Brigatinib (brigatinib)

Snippet

Sponsor: ETOP IBCSG Partners Foundation | Conditions: NSCLC, Stage III, ALK-rearrangement | Phase 2 | Status: WITHDRAWN